Biovail Narrows Revenue Guidance; Projected Earnings Remains Unchanged
This article was originally published in The Pink Sheet Daily
Executive Summary
The company revises its revenue guidance to $820-$920 mil. from $800-$940 mil. Estimate reflects stronger than expected Wellbutrin XL growth as well as lagging Cardizem LA, Teveten and Zovirax sales.